ClinicalTrials.gov
public full text
Public Domain
Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies
The primary objective of this research is to evaluate response to systemic therapy, including anti-angiogenesis therapy and/or immune-based therapies via 18F-DCFPyL prostate-specific membrane antigen (PSMA)-based positron emission tomography/computed tomography (PET/CT) in patients with metastatic renal cell carcinoma (RCC) and to compare qualitatively with conventional imaging response criteria - Response Evaluation Criteria In Solid Tumors (RECIST 1.1) and histopathological endpoints including isolation, enumeration and staining of Circulating Tumor Cells (CTC).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma#908533
- PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment#871250
- Measuring Treatment Response in Metastatic Renal Cell Cancer Using FPIA PET/CT#426787
- Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project#800570
- Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer#839027
Record · ID 849452
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive